Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIVORIFUNGOL: Early Voriconazole in Neutropenic Patients
NCT00386802Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Aug 2006
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of voriconazole in invasive fungal infection (IFI), sponsored by Fundación PETHEMA. Primary endpoint: Frequency of use of broad-spectrum antifungals in the episode of neutropenia at 2 years. Started Aug 2006; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00386802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386802.